Products Categories

CAS No.5026-62-0 Sodium met...

CAS No.3039-83-6 Sodium Eth...

CAS No.1304-76-3 Bismuth Tr...

CAS No.929-59-9 Pharmaceuti...

CAS No.143-19-1 Sodium Olea...

CAS No.129-18-0 Phenylbutaz...

CAS No.74-79-3 L-Arginine P...

CAS No.121-54-0 Benzethoniu...

CAS No.73-78-9 Lidocaine hy...

Procaine hydrochloride CAS ...

0102030405

CAS NO.124655-09-0 Intermediates of Rosuvastatin Calcium (2).png

CAS NO 1029872-54-5 Vemurafenib Pharmaceutical Intermediates

Product name	Vemurafenib
CAS No.	1029872-54-5
EINECS	800-227-2
Formula	C23H18ClF2N3O3S
Molecular Weight	489.9221264
Appearance	Off-White Solid
Purity	≥98%
Type	Pharmaceutical Intermediates

High Purity: Our vemurafenib is manufactured to the highest purity standards, ensuring reliable performance in pharmaceutical applications.

Targeted Therapy: This compound is designed specifically to inhibit the BRAF V600E mutation, providing an effective treatment for metastatic melanoma and other cancers.

Integrated Production and Trading: As a production and trading integrated factory, we provide competitive prices and a stable supply of high-quality chemicals.

Expertise and Experience: With many years of experience in chemical manufacturing, we guarantee that our products meet the highest industry standards.

Custom Solutions: We offer custom solutions to meet specific customer requirements, including custom synthesis and packaging options.

product details

Product details

Product detail

Vemurafenib is a potent and selective inhibitor of BRAF V600E kinase, a mutation commonly found in various cancers, especially melanoma. By specifically targeting this mutation, vemurafenib disrupts the signaling pathway that promotes cancer cell growth and proliferation. This targeted action makes vemurafenib a valuable treatment option for patients with BRAF V600E-positive metastatic melanoma, thereby improving survival and quality of life.

product detail

CAS No.	40856-44-8
EINECS	609-874-3
Formula	C9H11NO2
Molecular Weight	165.19
Appearance	White to Off-White solid
Purity	≥98%
Type	Pharmaceutical Intermediates

Advantages

1. Effective Treatment of Melanoma: Vemurafenib provides a targeted approach to treat BRAF V600E-positive metastatic melanoma with significant benefits in tumor response and patient survival.

2. Minimal side effects: Compared with traditional chemotherapy, vemurafenib has fewer side effects, so it is a suitable option for patients who may have adverse reactions to other treatments.

3. Customizable Formulation: Our integrated plant capabilities enable us to offer customizable formulations, enabling customers to develop specific dosage forms suitable for their target patient population.

4. Regulatory Compliance: We adhere to strict regulatory standards to ensure our products meet international quality and safety regulations and are suitable for pharmaceutical applications.

5. Reliable supply chain: As a production and trading integrated factory, we maintain a strong supply chain to ensure timely delivery and continuous supply of products.

Application

Vemurafenib is primarily used in the pharmaceutical industry to treat BRAF V600E-positive metastatic melanoma. Its unique mechanism of action enables it to effectively manage symptoms associated with this condition, including:

- Tumor Shrinkage: Vemurafenib has been shown to significantly reduce tumor size in patients with BRAF V600E mutations, thereby improving clinical outcomes.

- Combination Therapies: Ongoing studies are exploring the efficacy of vemurafenib in combination with other targeted therapies and immunotherapies to enhance treatment efficacy and overcome resistance.

- Other Indications: Vemurafenib is also being investigated for its potential use in other cancers carrying BRAF mutations, thereby expanding its therapeutic applications.

Physical and chemical properties

- Molecular formula: C23H18ClF2N3O3S

-Molecular weight:489.9221264 g/mol

- Appearance: Off-White Solid

- Solubility: Soluble in dimethyl sulfoxide (DMSO) and methanol; slightly soluble in water.

- Melting point: approx. 150-155°C

- Stability: Vemurafenib is stable under normal storage conditions. Keep in a cool and dry place away from direct sunlight. The recommended shelf life is two years.

Vemurafenib's physical and chemical properties make it an ideal candidate for a variety of applications in drug formulation and development. Its solubility properties allow it to be easily incorporated into different dosage forms, thereby improving bioavailability and therapeutic efficacy. The compound's stability ensures that it maintains its effectiveness throughout its shelf life, making it a reliable choice for pharmaceutical manufacturers.

In summary

In summary, vemurafenib is a high-quality pharmaceutical compound with great potential in the treatment of BRAF V600E-positive metastatic melanoma. With our commitment to quality, expertise and customer satisfaction, we are a trusted partner for all your pharmaceutical needs. Contact us today to learn more about our products and how we can support your drug development projects. Our commitment to innovation and excellence ensures that you receive the best possible products tailored to your specific requirements.